Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 3Phase NA 2Phase 1 2Phase 4 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Leukemia, Myeloid, Acute 35Neoplasm Metastasis 32Myelodysplastic Syndromes 18Lung Neoplasms 16Colorectal Neoplasms 14Pancreatic Neoplasms 12Breast Neoplasms 12Multiple Myeloma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Melanoma 9Glioblastoma 9Lymphoma, Follicular 8Carcinoma, Renal Cell 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 7Astrocytoma 7Ovarian Neoplasms 6Glioma 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Lymphoma, T-Cell 5Lymphoma, Mantle-Cell 5Leukemia, Biphenotypic, Acute 5Hematologic Neoplasms 5Stomach Neoplasms 4

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × Specimen Handling × Clear all
NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡